ROTFL. You mean holders don't want to hear facts. Their greed makes them think this one hit wonder orphan drug for a very rare medical condition will miraculously turn CUV into the next CSL.

Afamelanotide aka Melanotan I is a synthetic version of the hormone alpha-MSH. It was developed as a sunless tanning agent by the University of New Mexico in 1980. It has been out of patent for >20 years.

Proc Natl Acad Sci U S A.1980 Oct; 77(10): 5754–5758.

doi: 10.1073/pnas.77.10.5754

PMCID: PMC350149

PMID: 6777774

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

T K Sawyer, P J Sanfilippo, V J Hruby, M H Engel, C B Heward, J B Burnett, and M E Hadley

An alternative synthesis method was patented by Chinese researchers in 2016.
Preparation method of melanotan I
https://patents.google.com/patent/CN106243214B/en?q=melanotan&oq=melanotan


The only patents CUV has relate to subcutaneous implants and topical ointments for a small number of medical conditions.These patents will begin to expire in 2023.
https://patents.google.com/?assignee=clinuvel&oq=clinuvel


Scenesse is an Orphan Drug . This means it is far easier to get get FDA approval.

The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316.

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products

If CUV had so much potential why would they CEO be selling?